Masimo v. Apple: Federal Circuit Dismissal in Sensor Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Masimo Corp. c. Apple, Inc. |
| Numéro de dossier | 24-1625 (Fed. Cir.) |
| Tribunal | Federal Circuit, Appeal from PTAB (implied) |
| Durée | Apr 1, 2024 – Jan 16, 2026 1 year 9 months |
| Résultat | Voluntary Dismissal – No Ruling on Merits |
| Brevets en cause | |
| Produits incriminés | Apple Watch models (optical sensing components) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Global leader in noninvasive patient monitoring technology, holding an extensive portfolio of patents related to pulse oximetry and wearable health sensors.
🛡️ Défendeur
Leading consumer electronics company whose Apple Watch series has become a central battleground for health monitoring patents, integrating blood oxygen and optical sensor technologies.
Brevets en cause
At the center of this proceeding was **U.S. Patent No. 7,761,127 B2** (Application No. 11/366,209), directed to a **multiple wavelength sensor substrate**. This patent covers a foundational architecture used in optical sensors that measure biological data — such as blood oxygen saturation — across multiple light wavelengths. This technology is critical to wearable health monitors, including smartwatches.
- • US 7,761,127 B2 — Multiple wavelength sensor substrate
Developing optical health sensors?
Check if your sensor design might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The Federal Circuit dismissed the proceeding pursuant to Fed. R. App. P. 42(b) — a voluntary dismissal by stipulation of the parties. The order specified that each side shall bear its own costs, a standard condition in stipulated dismissals that signals a negotiated resolution rather than a clear-cut winner or loser. No damages were awarded, and no injunctive relief was issued at this appellate stage.
Principales questions juridiques
The **verdict cause is classified as “Patentability — Invalidity/Cancellation Action,”** indicating that Apple challenged the validity of U.S. Patent No. 7,761,127 B2, likely seeking cancellation of claims through a USPTO trial proceeding with subsequent appeal to the Federal Circuit. A Rule 42(b) dismissal at the appellate level typically reflects a **coordinated resolution across multiple fronts**, rather than an isolated appellate decision. The patent’s survival (or resolution by agreement) at the appellate stage means **U.S. Patent No. 7,761,127 B2 was not conclusively invalidated by this proceeding.** The claims covering the multiple wavelength sensor substrate remain part of Masimo’s enforceable portfolio unless addressed in other proceedings.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in wearable health sensor design. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View 47 related patents in the optical sensor technology space
- See which companies are most active in health sensor patents
- Understand claim construction patterns for sensor substrates
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Multiple wavelength sensor substrates
47 brevets connexes
In optical sensor design space
Options de contournement
Available for most sensor claims
✅ Points clés à retenir
Rule 42(b) stipulated dismissals at the Federal Circuit reflect strategic portfolio management, not litigation failure.
Rechercher la jurisprudence connexe →Invalidity challenges to foundational platform patents carry high appellate costs with uncertain outcomes.
Explorer les précédents →Foire aux questions
The case involved U.S. Patent No. 7,761,127 B2 (Application No. 11/366,209), directed to a multiple wavelength sensor substrate — core technology in optical health monitoring devices.
The proceeding was dismissed pursuant to Fed. R. App. P. 42(b) by mutual agreement of the parties, with each side bearing its own costs. No judicial ruling on the merits was issued.
The patent survived the appellate proceeding without cancellation, reinforcing its enforceability. Companies developing optical biosensor products should conduct updated FTO analysis against Masimo’s portfolio.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- USPTO Patent Center — U.S. Patent No. 7,761,127 B2
- PACER Federal Court Records
- United States Court of Appeals for the Federal Circuit — Rule 42 Procedures
- U.S. Patent and Trademark Office — Patent Trial and Appeal Board (PTAB)
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.